Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients

[1]  藤原章,et al.  Chromogenic in situ hybridization(CISH)法を用いたHER2遺伝子増幅の検討 , 2010 .

[2]  N. Sneige,et al.  Performance of chromogenic in situ hybridization on testing HER2 Status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) herceptest results: a study of two institutions using the conventional and new ASCO/CAP scoring criteria. , 2009, American journal of clinical pathology.

[3]  N. Sneige,et al.  Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations. , 2009, American journal of clinical pathology.

[4]  Marta Cuadros,et al.  Systematic Review of HER2 Breast Cancer Testing , 2009, Applied immunohistochemistry & molecular morphology : AIMM.

[5]  S. Rogatto,et al.  Quantitative real-time RT-PCR and chromogenic in situ hybridization: precise methods to detect HER-2 status in breast carcinoma , 2009, BMC Cancer.

[6]  K. Shen,et al.  Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer , 2008 .

[7]  A. Luini,et al.  HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17. , 2007, European journal of cancer.

[8]  Nandini Dendukuri,et al.  Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis , 2007, Canadian Medical Association Journal.

[9]  M. Dowsett,et al.  Standardization of HER2 testing: results of an international proficiency-testing ring study , 2007, Modern Pathology.

[10]  G. Sauter,et al.  Close association between HER-2 amplification and overexpression in human tumors of non-breast origin , 2007, Modern Pathology.

[11]  M. Kissin,et al.  Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer , 2006, Journal of Clinical Pathology.

[12]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.

[13]  Anne Vincent-Salomon,et al.  High inter-observer agreement in immunohistochemical evaluation of HER-2/neu expression in breast cancer: a multicentre GEFPICS study. , 2006, European journal of cancer.

[14]  G. Francis,et al.  Evaluation of oestrogen and progesterone receptor status in HER‐2 positive breast carcinomas and correlation with outcome , 2006, Pathology.

[15]  F. Marandino,et al.  Chromogenic in situ hybridization to detect HER-2/neu gene amplification in histological and ThinPrep-processed breast cancer fine-needle aspirates: a sensitive and practical method in the trastuzumab era. , 2006, The oncologist.

[16]  Andreas Makris,et al.  Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Cummings,et al.  Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry , 2006, Pathology.

[18]  K. Kwok,et al.  Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm , 2006, Modern Pathology.

[19]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[20]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[21]  M. Tonato,et al.  HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results. , 2005, Clinical breast cancer.

[22]  C. Vogel,et al.  Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. , 2005, Clinical breast cancer.

[23]  R. Knuechel,et al.  Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin‐embedded breast cancer , 2005, The Journal of pathology.

[24]  P. Lal,et al.  Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. , 2005, American journal of clinical pathology.

[25]  P. Lal,et al.  Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization? , 2005, American journal of clinical pathology.

[26]  Raymond R Tubbs,et al.  HER-2 testing in breast cancer. , 2004 .

[27]  N. Dandachi,et al.  Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assesment in breast cancer , 2004, Journal of Molecular Histology.

[28]  J. Isola,et al.  Interlaboratory Comparison of HER-2 Oncogene Amplification as Detected by Chromogenic and Fluorescence in situ Hybridization , 2004, Clinical Cancer Research.

[29]  J. Vera-Román,et al.  Comparative assays for the HER-2/neu oncogene status in breast cancer. , 2004, Archives of pathology & laboratory medicine.

[30]  Daniel Birnbaum,et al.  Identification and validation of an ERBB2 gene expression signature in breast cancers , 2004, Oncogene.

[31]  A. Vincent-Salomon,et al.  Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer , 2003, British Journal of Cancer.

[32]  A. Vincent-Salomon,et al.  Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French Multicentre GEFPICS * Study , 2003, Histopathology.

[33]  M. Dowsett,et al.  Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER‐2 in 426 breast carcinomas from 37 centres , 2003, The Journal of pathology.

[34]  S. Pepe,et al.  Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  Peter A Kaufman,et al.  Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. , 2002, Journal of the National Cancer Institute.

[36]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  D B Evans,et al.  Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[39]  S. Ménard,et al.  Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  A. Vincent-Salomon,et al.  Strong Correlation between Results of Fluorescent In Situ Hybridization and Immunohistochemistry for the Assessment of the ERBB2 (HER-2/neu) Gene Status in Breast Carcinoma , 2000, Modern Pathology.

[41]  D. Visscher,et al.  Determination of Her-2/Neu Status in Breast Carcinoma: Comparative Analysis of Immunohistochemistry and Fluorescent In Situ Hybridization , 2000, Modern Pathology.

[42]  S J Schnitt,et al.  Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  D Tripathy,et al.  Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  N. Hynes,et al.  The biology of erbB-2/neu/HER-2 and its role in cancer. , 1994, Biochimica et biophysica acta.

[45]  L. Presta,et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Douglas G. Altman,et al.  Practical statistics for medical research , 1990 .

[47]  A. Ullrich,et al.  p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor , 1989, Molecular and cellular biology.

[48]  M. J. van de Vijver,et al.  Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene , 1987, Molecular and cellular biology.

[49]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[50]  Jacob Cohen.  A Coefficient of Agreement for Nominal Scales , 1960 .